摘要
目的探讨醒脑静注射液治疗脑卒中伴意识障碍的临床疗效及安全性,总结经验以提高临床治疗水平及保证用药安全性。方法将2013-10—2015-04我科收治120例脑卒中伴意识障碍患者随机分成对照组和观察组,各60例,其中对照组给予神经内科常规综合治疗,观察组在对照组基础上给予醒脑静注射液治疗,记录相关临床资料并作回顾性分析。结果治疗7d后治疗组的GCS评分大于对照组,但差异无统计学意义(P>0.05);治疗14d后治疗组的GCS评分大于对照组,且差异具有统计学意义(P<0.05);观察组的总有效率大于对照组,且差异具有统计学意义(P<0.05);2组间不良反应发生率差异无统计学意义(P>0.05)。结论醒脑静注射液治疗脑卒中伴意识障碍能够有效提高患者的GCS评分,显著改善意识障碍状况,且用药安全。
Objective To investigate the clinical efficacy and safety of Xingnaojing injection in the treatment of stroke concomitant with unconsciousness,in order to improve the level of clinical treatment and guarantee drug safety via summarizing the experience of drug usage.Methods From October 2013 to April 2015 in our department,120 stroke patients accompanied with consciousness disorders were randomly divided into control group and observation group,60 cases in each group.Besides the routine comprehensive treatment for both two groups,the observation group received the Xingnaojing injection.Then we recorded the clinical data and retrospectively analyzed the related data.Result In terms of GCS scores,there was no significant difference between two groups after 7days treatment（P〉0.05）,while the observation group showed greater scores than the control group after 14 days treatment（P〈0.05）.Additionally,the total effective rate of the observation group was significantly higher than that of the control group（P〈0.05）.The two groups indicated no statistical difference as for incidence of adverse reactions（P〉0.05）.Conclusion Xingnaojing injection can effectively improve GCS scores and consciousness state with good safety.
出处
《中国实用神经疾病杂志》
2016年第10期23-24,共2页
Chinese Journal of Practical Nervous Diseases
